News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial for DESyne BD™ Novolimus Eluting Coronary Stent with Biodegradable Polymer



11/9/2011 9:04:35 AM

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month randomized clinical trial results today demonstrating the superiority of the Elixir DESyne™ BD Novolimus Eluting Coronary Stent System compared to the control Endeavor® Zotarolimus Eluting Coronary Stent System in the primary endpoint of in-stent late lumen loss and the secondary endpoint of binary restenosis.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES